Close

Oppenheimer Raises Price Target on NeuroDerm (NDRM) to $30 After Meeting with FDA

December 7, 2016 9:45 AM EST Send to a Friend
Oppenheimer reiterated an Outperform rating on NeuroDerm (NASDAQ: NDRM), and raised the price target to $30.00 (from $24.00), following an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login